PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.
Zacks
More News
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.
Zacks
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
AVTR's product breadth, digital upgrades and new pharma wins support growth, though VWR Distribution & Services remains a challenge.
Zacks
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
Zacks
Can MDT Stock Gain From Its Planned Acquisition of SPR Therapeutics?
Medtronic eyes a $650 million acquisition of SPR, adding the FDA-cleared SPRINT PNS System to expand its chronic pain treatment offerings ahead of the fiscal 2027 closing.
Zacks
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.
Zacks
MMED's Latest Study Supports the Strength of 780G SmartGuard Algorithm
MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.
Zacks
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
QGEN's new QIA Agent platform uses conversational AI to streamline experiment planning and ordering support.
Zacks
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL's strong Q1 earnings, digital growth and expanding high-tech platform support long-term upside despite rising cost pressures.
Zacks
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST's HVP business and GLP-1 demand are driving growth, but can Annex 1 tailwinds and margin gains offset inflation and SmartDose risks?